Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell therapy using human embryonic stem cells.

Sharon Gerecht-Nir1, Joseph Itskovitz-Eldor

  • 1Biotechnology Interdisciplinary Unit, Technion - Israel Institute of Technology, Haifa.

Transplant Immunology
|May 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selection for CD26<sup>-</sup> and CD49A<sup>+</sup> Cells From Pluripotent Stem Cells-Derived Islet-Like Clusters Improves Therapeutic Activity in Diabetic Mice.

Frontiers in endocrinology·2021
Same author

Derivation of Pericytes from Human Pluripotent Stem Cells.

Methods in molecular biology (Clifton, N.J.)·2021
Same author

Cardiac Fibroblast-Induced Pluripotent Stem Cell-Derived Exosomes as a Potential Therapeutic Mean for Heart Failure.

International journal of molecular sciences·2020
Same author

Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1<sup>G93A</sup> and NSG animal models.

Stem cell research & therapy·2018
Same author

20th Anniversary of Isolation of Human Embryonic Stem Cells: A Personal Perspective.

Stem cell reports·2018
Same author

Scalable Expansion of Pluripotent Stem Cells.

Advances in biochemical engineering/biotechnology·2017
Same journal

Clinical outcomes of myeloablative allogeneic peripheral blood stem cell transplantation for relapsed/refractory T-ALL/LBL: A single-center study.

Transplant immunology·2026
Same journal

Retrospective study on allogeneic hematopoietic stem cell transplantation for the treatment of Hemophagocytic lymphohistiocytosis.

Transplant immunology·2026
Same journal

HLA selected red cell transfusions to prevent HLA sensitisation: a prospective, double-blinded, randomised controlled trial.

Transplant immunology·2026
Same journal

Efficacy and safety of nilotinib in steroid-refractory chronic graft-versus-host disease: A systematic review and meta-analysis.

Transplant immunology·2026
Same journal

Evaluation of the bioassay for detecting early endothelial activation using microvascular cultures in renal transplant recipients.

Transplant immunology·2026
Same journal

Diagnostic performance of EUS-FNA for pancreatic lesions at tertiary centers in Iran without rapid on-site evaluation.

Transplant immunology·2026
See all related articles

Human embryonic stem cells (hESCs) offer potential for cell therapy due to their pluripotency. This review covers hESC derivation, safety, production, and differentiation for clinical applications.

Area of Science:

  • Stem cell biology
  • Regenerative medicine
  • Developmental biology

Background:

  • Cell therapy utilizes healthy cells to restore tissue function.
  • Stem cells possess self-renewal and differentiation capabilities.
  • Human embryonic stem cells (hESCs) are derived from pluripotent inner cell mass cells of blastocysts.

Purpose of the Study:

  • To review techniques for deriving and maintaining undifferentiated hESCs.
  • To address safety and bulk production challenges for clinical translation.
  • To detail the in vitro differentiation potential of hESCs.

Main Methods:

  • Review of scientific literature on hESC derivation and maintenance.
  • Analysis of safety and scalability considerations for hESC production.

Related Experiment Videos

  • Compilation of data on hESC differentiation in vitro.

    • Main Results:

    • Established methods for hESC derivation and culture are summarized.
    • Key safety concerns and strategies for large-scale hESC production are discussed.
    • Extensive in vitro differentiation capabilities of hESCs are documented.

    Conclusions:

    • hESCs hold significant promise as a source for cell-based therapies.
    • Further research into safety and production is crucial for clinical application.
    • Understanding hESC differentiation is key to harnessing their therapeutic potential.